NCT03130582|CompletedFDA Drug
High-dose Etoposide Could Discriminate Patients With Refractory/Relapsed Lymphoma Benefit From APBSCT
2008 WHO Myeloid and Lymphocytic Tumor Diagnostic Criteria
Loading search results
2008 WHO Myeloid and Lymphocytic Tumor Diagnostic Criteria
Sponsor study identifier
observational
88
0 countries
N/A
Study Start
November 2005
Actual (reported)Primary Completion
December 2014
Actual (reported)Study Completion
December 2016
Actual (reported)patients with refractory /relapsed lymphoma received high-dose etoposide for hematopoietic stem cell (HSC) mobilization.All patients received high-dose etoposide 20-25 mg/kg/d intravenously for two consecutive days followed by rhG-CSF10ug/kg/day subcutaneously at 48 hours after chemotherapy; rhG-CSF was continued until the end of harvesting for HSCs/HPCs. Peripheral blood counts were performed daily for all patients following the initiating of rhG-CSF. Leukapheresis was performed when peripheral blood white blood count exceeded 4×109/L with blood cell The harvested cells reached at least 2\*108/kg for mononuclear cells and/or 2\*106/kg for CD34+ cells with once to twice leukapheresis. The final product was kept frozen in liquid nitrogen.Auto-PBSCT
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 2016
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
November 2005
Actual (reported)December 2014
Actual (reported)December 2016
Actual (reported)April 22, 2017
Actual (reported)April 26, 2017
Actual (reported)death
death
10 years
CR
Complete response
10 years
relapse
relapse
10 years
an epipodophyllotoxin, is one of the most common chemotherapy agents for lymphoma without reciprocal resistance with other kinds of agents.
patients with refractory/relapsed lymphoma
88 participants (actual enrollment reported by the registry).
First Submitted
April 22, 2017
First Posted
April 26, 2017
Study Start
November 2005
Actual (reported)Contact the study team to confirm eligibility.
Primary Completion
December 2014
Actual (reported)Study Completion
December 2016
Actual (reported)Last Updated
April 28, 2017
Record last verified: 2017-04
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: